PRNewswire (Mon, 12-Jan 7:00 AM ET)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Fri, 2-Jan 4:05 PM ET)
Karyopharm to Participate in Baird's Biotech Discovery Series
PRNewswire (Mon, 8-Dec 7:00 AM ET)
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
PRNewswire (Mon, 1-Dec 7:00 AM ET)
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
PRNewswire (Mon, 3-Nov 7:00 AM ET)
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
PRNewswire (Mon, 27-Oct 7:00 AM ET)
Market Chameleon (Wed, 8-Oct 5:46 AM ET)
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Karyopharm Therapeutics trades on the NASDAQ stock market under the symbol KPTI.
As of January 20, 2026, KPTI stock price declined to $6.25 with 100,748 million shares trading.
KPTI has a beta of 1.77, meaning it tends to be more sensitive to market movements. KPTI has a correlation of 0.09 to the broad based SPY ETF.
KPTI has a market cap of $99.54 million. This is considered a Micro Cap stock.
Last quarter Karyopharm Therapeutics reported $44 million in Revenue and -$3.82 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.55.
In the last 3 years, KPTI traded as high as $73.05 and as low as $3.51.
The top ETF exchange traded funds that KPTI belongs to (by Net Assets): VTI, VXF, IWC.
KPTI has underperformed the market in the last year with a price return of -40.3% while the SPY ETF gained +16.8%. KPTI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +3.6% and -13.1%, respectively, while the SPY returned +3.8% and +0.1%, respectively.
KPTI support price is $5.94 and resistance is $6.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KPTI shares will trade within this expected range on the day.